SPIRIVA: payments to doctors
Payments that named SPIRIVA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $499K
- Providers
- 3,114
- Transactions
- 4,990
- Average per transaction
- $100
The per-transaction average — $100 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3,114 providers the average total is $160, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Boehringer Ingelheim | $430,518 | 86.3% |
| Boehringer Ingelheim International GmbH | $51,969 | 10.4% |
| Boehringer Ingelheim Do Brasil Quimica E Farmaceutical Ltda. | $16,601 | 3.3% |